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Abstract
Introduction: Presepsin, the circulating soluble form of CD14 subtype (sCD14-ST) is a new emerging early marker for sepsis. Various cutoff levels of 
presepsin have been proposed, to discriminate between systemic bacterial and nonbacterial infectious diseases. The aim of this work was to define 
the reference interval for presepsin according to the CLSI C28-A3c approved guideline.
Materials and methods: Reference individuals (N = 200; 120 females) aged 18-75 years (median 39 years), free from inflammatory diseases, were 
selected for the study. Presepsin concentrations were measured by a commercially available chemiluminescent enzyme immunoassay (PATHFASTTM, 
Mitsubishi Chemical Europe GmbH, Düsseldorf, Germany). Reference limits were calculated using the non-parametric percentile method. 
Results: Overall, the reference limits for the presepsin were 55–184 pg/mL (90% confidence intervals, CI, were 45 to 58 and 161 to 214, respec-
tively). There were no significant differences between males and females and the presepsin concentrations were not even particularly influenced 
by age. The upper reference limit for the presepsin is much lower than every cut-off limit so far proposed, both for sepsis and also for systemic in-
flammatory response syndrome. 
Conclusion: Specific decision levels are required to define the diagnostic and prognostic roles of presepsin in different settings of inflammatory and 
infectious diseases. Reference values can help to distinguish and quickly rule out healthy subjects or patients with other pathologies.
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CD14, a cluster differentiation (CD) marker protein, 
is a multifunctional cell surface glycoprotein, 
which exists as a membrane-anchored form or in a 
circulating soluble form. The circulating soluble 
form of CD14 subtype (sCD14-ST), presepsin, is 
mainly used in acute care settings, such as emer-
gency department and critical care, to distinguish 
between sepsis and systemic inflammatory re-
sponse syndrome (SIRS) and for early detection of 
a possible bacterial cause (1-3). Recently it has also 
been proposed as a marker of the appropriateness 
of antibiotic therapy in patients with severe sepsis 
or septic shock (4).
The cutoff values of presepsin for distinguishing 
systemic bacterial and nonbacterial infectious dis-
eases are usually very high, 600 pg/mL or over, in 
order to obtain a sufficient specificity. Different 
concentration levels of presepsin, regarding con-
trols groups, have been variously reported in re-
cent studies (5,6). Notwithstanding the fact that 
the traditional, widespread and practiced method 
for interpreting laboratory results is based on the 
comparison made with reference intervals (7), ref-
erence limits for this marker are not available at 
the moment.
The aim of this study is to determine the reference 
intervals of presepsin, according to the Clinical 
and Laboratory Standard Institute (CLSI) approved 
guideline C28-A3c (8).
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Materials and methods
Subjects
Reference subjects were selected from the sub-
jects seen at one of our blood collection centres 
for a complete blood count (CBC) test, over a peri-
od of one week, at the end of November 2013. All 
the individuals were fasting. Subjects were asked 
by one of us (MC) if they were free from fever, mus-
cle aches, headache, weakness and not receiving 
antibiotics therapy. Further exclusion criteria were 
pregnancy, chemotherapy, and having test for in-
fectious diseases, C-reactive protein (CRP) and/or 
erythrocyte sedimentation rate (ESR).
Informed consent to use leftover plasma was ob-
tained from all the participants at the time of 
blood sampling. Samples were collected between 
7.00 and 10.00 am. Samples were made anony-
mous upon freezing, keeping only the information 
about age (in years) and gender.
Methods
For this study only leftover blood specimens, col-
lected for a CBC test, were used. Blood samples 
were collected in endotoxin-free tubes containing 
ethylenediaminetetraacetate, in a K2EDTA Vacu-
ette tube, 13 x 75 mm, 3.5 mL, Greiner, Bio-One 
GmBH (Kremsmünster, Germany).
Leftover plasma was recovered by centrifuging 
the K2EDTA tube at 3,000 x g for 10 min, at the end 
of CBC analysis, within 3 hours from collection. 
Separated plasma was immediately frozen at -70 
°C until being assayed (stored for a month).
Presepsin concentrations were measured by a rap-
id, commercially available chemiluminescent en-
zyme immunoassay (CLEIA) based on a noncom-
petitive CLEIA combined with Magtration® tech-
nology (9). The method was optimized on an auto-
mated immunoassay analyzer, PATHFAST™, Mit-
subishi Chemical Europe GmbH, (Düsseldorf, Ger-
many) (10). Total coefficient of variation (CV) of the 
method in plasma is declared to be between 3.8% 
and 5.0%, in a wide range of concentrations (11). 
Samples were measured over three consecutive 
days, using reagents from the same lot and the 
same calibration. A quality control assay (two lev-
els) was performed after calibration to check the 
calibration curves and repeated at the end of the 
last sample. 
Statistical analysis
Reference limits were calculated according to the 
non-parametric percentile method (CLSI standard 
C28-A3c) (8), since data was not normally distrib-
uted (evaluated by Shapiro-Wilk test). For the male 
subgroup the “robust method” was used as rec-
ommended by the CLSI C28-A3 guideline when 
samples sizes are small, with less than 120 data. 
The robust method has the appeal of the paramet-
ric method in that it does not require as many ob-
servations as the nonparametric procedure. With 
the robust method, the confidence intervals for 
the reference limits are estimated using bootstrap-
ping (percentile interval method) (12). In boot-
strapping, the data of the samples are used to cre-
ate a large set of new “bootstrap” samples, simply 
by randomly taking data from the original sample 
(in this case, 10,000 iterations). Statistical signifi-
cance was evaluated by the observation of lack in 
overlap of the CI of the reference limits.
Age related reference intervals were also estimat-
ed (13,14), by z-scores normal distribution analysis. 
Statistical analysis was carried out by using Med-
calc® statistical software (v.14.8.1, Frank Schoon-
jans, Mariakerke, Belgium) (15). 
Results
A total of 200 subjects were included in the study, 
120 females and 80 males, aged 18-72 years and 
18-75 years (median age 36 and 46 years), respec-
tively. The reference limits for the presepsin were 
55–184 pg/mL. The CI limits and the differences 
between female and male are summarized in ta-
ble 1 and Figure 1. A relationship model between 
age and reference intervals is represented in figure 
2. For ages 20, 30, 40, 50, 60 and 70 years the 0.025 
and 0.975 centiles of estimated presepsin was 52-
182, 49-165, 53-168, 63-176, 76-172, 85-143 pg/mL, 
respectively. A slight increase in the concentra-
tions of presepsin is apparently associated with 
age. A reduction of inter-individual variability is 
observed after age 50, for both genders.
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Sample size 120 80 200
Lower limit 55 59 55
(90% CI) (45 to 57) (53 to 65) (45 to 58)
Upper limit 196 182 184
(90%CI) (161 to 214) (160 to 207) (161 to 214)
Table 1. 95% Reference limits for presepsin (pg/mL), according to non-parametric percentile method (CLSI C28-A3c) for females and 
all; for male subjects the “robust method” was used, as described in the same standard.
Figure 2. Relationship between age and presepsin concentra-
tions. 
The continuous lines represent 0.025 and 0.975 centiles, the 
dotted line the median values.
Figure 1. Comparison graph of presepsin concentration levels 
between female and male reference subjects. 
The middle line represents the median. Error bars represent the 
reference limits, calculated by the non-parametric percentile 
method percentile for females (continuous line) and by the ro-








































Data of this study show presepsin reference values 
55 and 184 pg/mL, with negligible differences be-
tween males and females. Presepsin is normally 
present in very low concentrations in the serum of 
healthy individuals and it has been shown to in-
crease in response to bacterial infections, accord-
ing to the severity of the disease. Previously, other 
studies reported ranges of presepsin concentra-
tions in control groups, compared to concentra-
tions in patient groups with infectious diseases. 
Data from these studies are not univocal and dif-
ferent cut-offs were proposed for clinical use of 
this marker. Endo et al. reported a median value of 
presepsin concentration of 312 pg/mL, ranged be-
tween 71 and 9,036 pg/mL, in 70 patients admit-
ted to the emergency room with not infectious 
disease. The authors determined an optimal pre-
sepsin cutoff value of 600 pg/mL to distinguish 
bacterial and nonbacterial infectious diseases (2). 
A cut-off point near 600 pg/mL was confirmed by 
Ulla et al. (16), with clinical sensitivity and specifici-
ty ranging from 0.79 to 0.87 and 0.61 to 0.81 re-
spectively. Shozushima et al. reported “normal 
control” values of 294.2 ± 121.4 pg/mL, obtained 
from 128 healthy subjects (100 men and 28 wom-
en) assessed as controls. They also obtained simi-
lar sensitivity and specificity (0.80 and 0.81 respec-
tively) to previous studies by using a lower cut-off, 
415 pg/mL (17). Recently, presepsin was evaluated 
by Chenevier-Gobeaux et al. (18) in 144 consecu-
tive patients at the emergency department (ED) 
without acute infection or acute/unstable disor-
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der, and 54 healthy participants. In the healthy 
subjects the presepsin median concentration was 
202 pg/mL (167-266 interquartile range), but the 
95th percentile of presepsin values in the ED pop-
ulation was 750 pg/mL. The authors found a sig-
nificantly increased presepsin concentration in pa-
tients aged over 70 years vs. younger patients (470 
[380-601] ng/L vs. 300 [201-457] ng/L, P < 0.001). 
Prevalence of elevated presepsin values was in-
creased in patients in comparison to control sub-
jects (80% vs. 13%, P < 0.001), and in patients aged 
≥ 70 years compared to younger patients (87% vs. 
47%, P < 0.001). Presepsin concentrations were 
also significantly increased in patients with kidney 
dysfunction. 
The variability of presepsin concentrations in the 
control subjects, which is observed in various 
studies, can depend on the selection bias of the 
“reference” subjects. 
The availability of reference values for this marker 
might be of some interest, considering that new 
and less elevated discriminant decision levels were 
published recently (Liu et al., 317 pg/mL) (19), while 
other studies confirmed higher cut-offs (Romual-
do et al., 729 pg/mL) (20). 
We found the upper reference limit is 184 pg/mL. 
This limit is lower than the previous cut-off limits 
for sepsis, but also lower than the values obtained 
in control groups in other studies. The cut-offs 
proposed so far are derived from analysis of the 
best diagnostic efficiency of the test, in distin-
guishing between bacterial and non-bacterial in-
fections in still critical patients. When healthy sub-
jects, not affected by inflammatory diseases were 
considered, the maximum values of presepsin 
could be lower. Moreover it could also be due to the 
selection criteria of reference subjects and in the 
standardization of the pre-analytical conditions.  
All our reference individuals were fasting, samples 
were collected between 7.00 and 10.00 in the 
morning, in a sitting position; any possible inflam-
matory process was investigated as exclusion cri-
teria.
Lower and upper reference limits for female and 
male subjects showed overlapping 90% CI and the 
differences could be due to chance.
Lastly, concentration levels of presepsin are not 
even particularly influenced by age contrary to 
what was recently found in the ED population (18). 
Our data suggest that it is reasonable to adopt a 
single reference interval (21). 
Specific decision levels are required to define diag-
nostic and prognostic roles of presepsin in differ-
ent settings of inflammatory and infectious diseas-
es. It was argued that presepsin could provide ad-
ditional information to values of CRP and procalci-
tonin (PCT) in the early diagnosis of sepsis (22). 
CRP demonstrates high sensitivity but very low 
specificity. PCT has gained a significant diagnostic 
role in this field, but this biomarker tends to rise 
transiently in non-septic conditions and SIRS, e.g., 
invasive trauma, surgery, heatstroke and physical 
exercise. Several studies compared the presepsin 
diagnostic power to that of PCT in detecting sepsis 
in patients with a documented or suspected infec-
tion, demonstrating the ability to differentiate be-
tween patients with bacterial and non-bacterial 
infections (2,23). 
The availability of reference values for presepsin 
concentration can help to distinguish and quickly 
rule out healthy subjects. It is also helpful in risk 
stratification and therapy monitoring, fields in 
which the role of presepsin has yet to be clarified. 
One of the limitations of this study was not to have 
considered a more representative sample of elder-
ly subjects and to have limited the analysis to indi-
viduals up to 75 years. Furthermore, in the selec-
tion of reference individuals, we did not evaluate 
diseases other than inflammatory pathologies 
(such as kidney diseases, metabolic disorders, etc.). 
Nevertheless, we found very low concentrations of 
presepsin in the reference subjects, defining a 
unique reference interval for females and males 
and for every age group. The availability of refer-
ence values according to the CLSI C28-A3c ap-
proved guideline could be helpful for future evalu-
ations of this new marker for sepsis.
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